Sign in or create an account to add this stock to your watchlist.
About The Joint (NASDAQ:JYNT)
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Industry, Sector and Symbol
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JYNT
CUSIPN/A
Phone480-245-5960
Debt
Debt-to-Equity Ratio0.95
Current Ratio1.17
Quick Ratio1.34
Price-To-Earnings
Trailing P/E Ratio-29.20
Forward P/E Ratio91.25
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.16 million
Price / Sales3.94
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book91.25
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-3,270,000.00
Net Margins-7.58%
Return on Equity-53.03%
Return on Assets-12.05%
Miscellaneous
Employees148
Outstanding Shares13,590,000
The Joint (NASDAQ:JYNT) Frequently Asked Questions
What is The Joint's stock symbol?
The Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were The Joint's earnings last quarter?
The Joint (NASDAQ:JYNT) posted its earnings results on Thursday, May, 10th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $7.10 million for the quarter, compared to analysts' expectations of $6.78 million. The Joint had a negative return on equity of 53.03% and a negative net margin of 7.58%. View The Joint's Earnings History.
When is The Joint's next earnings date?
What price target have analysts set for JYNT?
4 analysts have issued twelve-month target prices for The Joint's shares. Their predictions range from $5.70 to $10.00. On average, they anticipate The Joint's share price to reach $7.15 in the next year. View Analyst Ratings for The Joint.
What are Wall Street analysts saying about The Joint stock?
Here are some recent quotes from research analysts about The Joint stock:
- 1. Maxim Group analysts commented, "1Q18 revenue of $7.10M, up 28.9% y/y, was relatively inline with both our estimate of $7.18M and consensus of $7.06M.." (5/11/2018)
- 2. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (5/10/2018)
Who are some of The Joint's key competitors?
Some companies that are related to The Joint include Acacia Research (ACTG), Quarterhill (QTRH), Digital Turbine (APPS), Liberty Tax Service (TAX), MGT Capital Investments (MGTI), Finjan (FNJN), Copytele (ITUS), XCel Brands (XELB), Marathon Patent Group (MARA), Research Frontiers (REFR), ARC Group (ARCK), XpresSpa Group (XSPA), GlobalOptions Group (WLKR), Spherix (SPEX) and Health Discovery (HDVY).
Who are The Joint's key executives?
The Joint's management team includes the folowing people:
- Mr. Peter D. Holt, Chief Exec. Officer, Pres and Director (Age 59)
- Mr. John P. Meloun, Chief Financial Officer (Age 41)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Ms. Donna Smith, VP of Marketing
When did The Joint IPO?
(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Has The Joint been receiving favorable news coverage?
Press coverage about JYNT stock has trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Joint earned a daily sentiment score of 0.07 on Accern's scale. They also assigned media stories about the company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are The Joint's major shareholders?
The Joint's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include GLENHILL ADVISORS LLC (3.80%), Boston Partners (2.10%) and Bard Associates Inc. (0.56%). Company insiders that own The Joint stock include Bret Sanders, David M Orwasher, Glenhill Advisors Llc, James H Amos Jr, John P Meloun, Peter D Holt and Richard A Kerley. View Institutional Ownership Trends for The Joint.
Which major investors are buying The Joint stock?
JYNT stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners and Bard Associates Inc.. Company insiders that have bought The Joint stock in the last two years include Bret Sanders, Glenhill Advisors Llc, James H Amos Jr, John P Meloun, Peter D Holt and Richard A Kerley. View Insider Buying and Selling for The Joint.
How do I buy shares of The Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $7.30.
How big of a company is The Joint?
The Joint has a market capitalization of $99.24 million and generates $25.16 million in revenue each year. The company earns $-3,270,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. The Joint employs 148 workers across the globe.
How can I contact The Joint?
The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for The Joint (JYNT)
MarketBeat's community ratings are surveys of what our community members think about The Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
The Joint (NASDAQ:JYNT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for The Joint in the last 12 months. Their average twelve-month price target is $7.15, suggesting that the stock has a possible downside of 2.05%. The high price target for JYNT is $10.00 and the low price target for JYNT is $5.70. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.15 | $6.8167 | $6.15 | $6.15 |
| Price Target Upside: | 2.05% downside | 0.39% upside | 65.32% upside | 65.32% upside |
The Joint (NASDAQ:JYNT) Consensus Price Target History
The Joint (NASDAQ:JYNT) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
The Joint (NASDAQ:JYNT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
The Joint (NASDAQ JYNT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 50.80%
The Joint (NASDAQ JYNT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Peter D Holt | CEO | Buy | 7,125 | $7.74 | $55,147.50 | 50,945 |  |
| 6/30/2017 | James H Amos Jr | Director | Buy | 10,000 | $3.85 | $38,500.00 | 57,295 | |
| 6/30/2017 | Peter D Holt | Insider | Buy | 3,820 | $3.76 | $14,363.20 | 43,820 | |
| 6/27/2017 | John P. Meloun | CFO | Buy | 6,850 | $3.69 | $25,276.50 | | |
| 3/29/2017 | James H Amos Jr | Director | Buy | 10,000 | $3.98 | $39,800.00 | 29,345 | |
| 3/28/2017 | Glenhill Advisors Llc | Major Shareholder | Sell | 86,428 | $3.40 | $293,855.20 | | |
| 3/27/2017 | Glenhill Advisors Llc | Major Shareholder | Sell | 43,214 | $3.13 | $135,259.82 | | |
| 3/24/2017 | Peter D Holt | CEO | Buy | 10,000 | $3.52 | $35,200.00 | 40,000 | |
| 12/14/2016 | James H Amos Jr | Director | Buy | 10,000 | $2.22 | $22,200.00 | 27,345 | |
| 12/1/2016 | Bret Sanders | Director | Buy | 10,000 | $2.19 | $21,900.00 | 35,345 | |
| 9/22/2016 | David M Orwasher | Insider | Sell | 5,000 | $2.40 | $12,000.00 | 117,723 | |
| 9/12/2016 | David M Orwasher | Insider | Sell | 5,000 | $2.82 | $14,100.00 | 122,723 | |
| 9/7/2016 | David M Orwasher | Insider | Sell | 4,200 | $3.01 | $12,642.00 | 127,723 | |
| 9/2/2016 | David M Orwasher | Insider | Sell | 1,702 | $2.80 | $4,765.60 | 133,524 | |
| 8/29/2016 | Peter D Holt | CEO | Buy | 30,000 | $2.66 | $79,800.00 | 10,000 | |
| 8/29/2016 | Richard A Kerley | Director | Buy | 7,000 | $2.78 | $19,460.00 | 18,285 | |
| 8/26/2016 | Richard A Kerley | Director | Buy | 5,000 | $2.18 | $10,900.00 | 18,285 | |
| 8/9/2016 | David M Orwasher | Insider | Sell | 10,000 | $2.18 | $21,800.00 | 133,625 | |
| 7/11/2016 | David M Orwasher | Insider | Sell | 5,000 | $2.13 | $10,650.00 | 143,625 | |
| 7/1/2016 | Glenhill Advisors Llc | Major Shareholder | Buy | 80,069 | $1.97 | $157,735.93 | | |
| 6/29/2016 | David M Orwasher | Insider | Sell | 10,000 | $2.38 | $23,800.00 | 151,625 | |
| 6/27/2016 | David M Orwasher | Insider | Sell | 7,000 | $2.50 | $17,500.00 | 151,625 | |
| 6/20/2016 | David M Orwasher | Insider | Sell | 600 | $2.80 | $1,680.00 | 158,625 | |
| 6/10/2016 | David M Orwasher | Insider | Sell | 1,700 | $3.06 | $5,202.00 | 160,625 | |
| 6/8/2016 | David M Orwasher | Insider | Sell | 150 | $3.04 | $456.00 | 160,925 | |
| 6/6/2016 | David M Orwasher | Insider | Sell | 2,300 | $3.06 | $7,038.00 | 161,075 | |
| 6/2/2016 | David M Orwasher | Insider | Sell | 2,100 | $3.17 | $6,657.00 | 163,375 | |
| 6/1/2016 | David M Orwasher | Insider | Sell | 2,400 | $3.05 | $7,320.00 | 165,475 | |
| 3/30/2016 | Glenhill Advisors Llc | Major Shareholder | Buy | 46,465 | $3.10 | $144,041.50 | | |
| 3/30/2016 | James H Amos Jr | Director | Buy | 5,000 | $3.39 | $16,950.00 | 5,000 | |
| 3/29/2016 | Ronald V Davella | Director | Buy | 3,000 | $3.14 | $9,420.00 | 3,000 | |
| 3/28/2016 | John B Richards | CEO | Buy | 3,295 | $2.98 | $9,819.10 | 429,245 | |
| 3/23/2016 | Richard A Kerley | Director | Buy | 900 | $3.41 | $3,069.00 | 940 | |
| 3/22/2016 | Francis T Joyce | CFO | Buy | 2,000 | $3.27 | $6,540.00 | 95,500 | |
| 3/22/2016 | Steve Colmar | Director | Buy | 6,000 | $3.38 | $20,280.00 | 4,700 | |
| 3/21/2016 | Bret Sanders | Director | Buy | 7,580 | $3.26 | $24,710.80 | 13,000 | |
| 3/21/2016 | John B Richards | CEO | Buy | 7,450 | $3.31 | $24,659.50 | 425,950 | |
| 11/20/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 651,842 | $5.50 | $3,585,131.00 | | |
| 11/20/2015 | John B Richards | CEO | Buy | 18,000 | $5.50 | $99,000.00 | 418,500 | |
| 5/15/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 12,820 | $9.49 | $121,661.80 | | |
| 4/2/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 5,669 | $7.80 | $44,218.20 | | |
| 3/31/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 2,289 | $7.35 | $16,824.15 | | |
| 3/24/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 5,686 | $7.33 | $41,678.38 | | |
| 3/3/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 2,915 | $7.99 | $23,290.85 | | |
| 2/27/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 2,246 | $7.97 | $17,900.62 | | |
| 1/30/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 38,981 | $6.44 | $251,037.64 | | |
| 1/2/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 7,485 | $6.35 | $47,529.75 | | |
(Data available from 1/1/2013 forward)
The Joint (NASDAQ JYNT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Peter D. Holt Purchases 7,125 Shares of The Joint (JYNT) Stock
www.americanbankingnews.com - May 16 at 4:41 PM |
 | Edited Transcript of JYNT earnings conference call or presentation 8-Mar-18 10:00pm GMT
finance.yahoo.com - May 14 at 4:18 PM |
 | The Joint Corp. reduces first quarter losses
www.bizjournals.com - May 13 at 10:07 AM |
 | The Joint's (JYNT) CEO Peter Holt on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:23 AM |
| The Joint (JYNT) Posts Earnings Results, Hits Estimates
www.americanbankingnews.com - May 12 at 12:28 AM |
| The Joint's (JYNT) "Buy" Rating Reiterated at Maxim Group
www.americanbankingnews.com - May 11 at 8:03 PM |
| Entrepreneur: Turnaround CEO adjusts chiropractic operations
finance.yahoo.com - May 11 at 4:18 PM |
| Joint misses by $0.01, beats on revenue
seekingalpha.com - May 11 at 10:42 AM |
| The Joint Corp. Reports First Quarter Financial Results
finance.yahoo.com - May 10 at 4:24 PM |
| The Joint (JYNT) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 10 at 4:23 PM |
| The Joint (JYNT) & RPX (RPXC) Critical Survey
www.americanbankingnews.com - May 2 at 10:10 AM |
| The Joint (JYNT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 28 at 1:34 AM |
| The Joint (JYNT) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 26 at 2:04 PM |
| The Joint Corp. to Host Conference Call on Thursday, May 10, to Discuss First Quarter 2018 Results
finance.yahoo.com - April 26 at 9:27 AM |
| 4 Breakout Stocks Offering Phenomenal Returns
finance.yahoo.com - April 24 at 9:38 AM |
| The Joint (JYNT) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - April 15 at 3:27 PM |
| Joint (JYNT) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 14 at 7:21 AM |
| Reviewing Joint (JYNT) & RPX (RPXC)
www.americanbankingnews.com - April 13 at 11:37 PM |
| Joint (JYNT) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 13 at 11:01 AM |
| Joint (JYNT) Price Target Raised to $9.00
www.americanbankingnews.com - April 12 at 10:45 AM |
 | The Joint Corp. (JYNT) Repurchases a Franchised Clinic in San Diego, No Terms Disclosed
www.streetinsider.com - April 10 at 10:07 AM |
 | The Joint Corp. Acquires Clinic in San Diego
feeds.benzinga.com - April 9 at 7:49 AM |
| Joint (JYNT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:27 AM |
| Joint (JYNT) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 3 at 10:13 AM |
| Joint Corp (JYNT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 3 at 1:48 AM |
| Critical Comparison: Liberty Tax Service (TAX) and Joint (JYNT)
www.americanbankingnews.com - April 1 at 1:16 PM |
| Acacia Research (ACTG) vs. Joint (JYNT) Financial Analysis
www.americanbankingnews.com - April 1 at 11:06 AM |
| Joint (JYNT) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 29 at 11:18 PM |
| Critical Survey: Joint (JYNT) and InVitae (NVTA)
www.americanbankingnews.com - March 29 at 1:22 PM |
| Joint (JYNT) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:39 PM |
 | Will Joint Corp (JYNT) Continue to Surge Higher?
www.zacks.com - March 29 at 10:06 AM |
| Joint (JYNT) Research Coverage Started at Lake Street Capital
www.americanbankingnews.com - March 28 at 9:16 AM |
| Joint (JYNT) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 7:10 AM |
| Joint (JYNT) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - March 9 at 9:04 PM |
| Joint Corp (JYNT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 9 at 1:42 AM |
| Joint (JYNT) Issues Earnings Results
www.americanbankingnews.com - March 9 at 12:38 AM |
| The Joint Corp. Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 5:05 PM |
| Joint (JYNT) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 1 at 1:12 AM |
| The Joint Corp. to Present at the 30th Annual ROTH Conference
finance.yahoo.com - February 26 at 9:33 AM |
| Contrasting Joint (JYNT) & iKang Healthcare Group (KANG)
www.americanbankingnews.com - February 22 at 2:26 PM |
| The Joint Corp. to Host Conference Call on Thursday, March 8, to Discuss Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 22 at 9:28 AM |
| The Joint Corp. Opens 400th Clinic
finance.yahoo.com - January 18 at 4:53 PM |
| Joint Corp (JYNT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 18 at 1:42 AM |
| ValuEngine Upgrades Joint (JYNT) to "Hold"
www.americanbankingnews.com - January 1 at 7:28 PM |
| The Painful Side Effect to Gifting Gadgets this Holiday Season
finance.yahoo.com - December 18 at 11:52 AM |
| UnitedHealth on A.M.Best's Radar After Buyout Announcement
finance.yahoo.com - December 8 at 11:34 AM |
| ETFs with exposure to The Joint Corp. (United States) : November 30, 2017
finance.yahoo.com - November 30 at 3:41 PM |
| Is It Advisable to Add Centene (CNC) to Your Portfolio?
finance.yahoo.com - November 29 at 3:43 PM |
| UnitedHealth Keeps '17 Guidance & Issues '18 View, Stock Up
finance.yahoo.com - November 29 at 3:43 PM |
| The Joint Corp. (United States) :JYNT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 11:21 AM |
The Joint (NASDAQ:JYNT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
The Joint (NASDAQ:JYNT) Income Statement, Balance Sheet and Cash Flow Statement
The Joint (NASDAQ JYNT) Stock Chart for Monday, May, 21, 2018
Loading chart…
